|
Navitoclax 923564-51-6, buy Navitoclax, Navitoclax & more.">Navitoclax those carrying the HER2 Ins774YVMA insertion mutation, but not in those with KRAS mutations.48 In an NSCLC cell line harboring the EGFR T790M mutation that maintained HER3/PI3K/Akt phosphorylation, PF-00299804, but not gefitinib, completely inhibited the HER3 signaling pathway and caused substantial apoptosis. 48 Similarly, in tumor xenograft models harboring the EGFR T790M mutation, PF-00299804, but not gefitinib, was effective in inhibiting tumor growth.48 PF-00299804 was also evaluated in A431 human squamous cell carcinoma and H125 human NSCLC xenograft models.54 In the A431 xenografts, PF-00299804 was administered once daily for 14 days, producing an average tumor growth delay of 45 days at a dose of 11 mg/kg. Several animals had a PR or a CR, defined as reductions in tumor mass of P50% and P75% from baseline, respectively, at doses of 11–100 mg/kg. In H125 xenografts, PF- 00299804 at doses of 30 or 65 mg/kg once daily for 14 days produced tumor growth delays of 9.1 and 10.2 days, respectively, although none of the animals had a PR or a CR. In these models, mean body weight declined by approximately 20% in animals treated with PF-00299804 at doses of 30 mg/kg or more.54 In a 2-arm, phase II trial evaluating PF-00299804 in patients with advanced NSCLC who had failed 1 or 2 prior chemotherapy regimens as well as prior treatment with erlotinib, patients with adenocarcinomas were enrolled in 1 arm of the study and patients with other NSCLC histologies were enrolled in the other arm.55 Preliminary results have been reported for the first 66 patients: 44 patients with adenocarcinomas and 22 patients with nonadenocarcinomas. 55 As of August 2009, of 36 evaluable patients with adenocarcinoma and 5 patients with non-adenocarcinoma, the DCR was 67% and 40%, respectively; SD >6 months occurred in 2 patients with adenocarcinoma and 1 patient with non-adenocarcinoma. 55 The most common Navitoclax 923564-51-6 AEs of any grade were diarrhea (82%), skin toxicity (77%), fatigue (59%), stomatitis (28%), and vomiting (23%).55 This study suggests that PF-00299804 may have clinical activity in patients with advanced NSCLC after the failure of prior chemotherapy and erlotinib. In the first-line setting, PF-00299804 is being tested in a phase II, open-label trial in patients with advanced lung carcinoma who were never smokers or former light smokers.56 Among the first 29 evaluable patients, there was 1 CR, 6 PRs, and 16 patients with SD for P16 weeks. In a subanalysis of 14 evaluable patients with EGFR mutation-positive disease, tumor shrinkage was observed in all cases. The most common treatment-related AEs were diarrhea and dermatitis acneiform for all grade events (79% and 49%, respectively) and grade 3 events (9% for both). Another phase II trial evaluated PF-00299804 vs erlotinib as second-line or third-line therapy in 188 patients with advanced NSCLC. PF-00299804 was associated with improvements in median PFS (HR, 0.681; 95% CI, 0.490–0.945; P = 0.019) and objective buy Navitoclax RR (17.0% vs 4.3%; P = 0.009) and clinical benefit rate (response or SDP24 weeks; 27.7% vs 13.8%; P = 0.03).57 However, there were imbalances between treatment arms of this study in the percentage of patients with performance status of 2 (PF-00299804, 19.1% vs erlotinib, 3.2%) and with tumors harboring EGFR mutations (PF-00299804, 20.2% vs erlotinib, 11.7%).57 PF-00299804 is being evaluated in patients with KRAS wild-type NSCLC refractory to at least 1 chemotherapy regimen and erlotinib in another phase II study.58 Among 62 evaluable patients, 3 achieved a PR and 35 had SD. AEs included diarrhea (86%), fatigue (40%), rash (45%), and stomatitis/mucosal inflammation (23%). In Korea, an open-label, single-arm Buy from the biotech company which is well known by scientists and drug discovery researchers worldwide for novel kinase inhibitors. Vist us to get more information regarding life reagents like Navitoclax 923564-51-6, buy Navitoclax, Navitoclax & more.
Related Articles -
Navitoclax 923564-51-6, buy Navitoclax, Navitoclax,
|
